Literature DB >> 16636306

Effect of nitric oxide synthase inhibition on proteinuria in glomerular immune injury.

Prasun K Datta1, Mukut Sharma, Pu Duann, Elias A Lianos.   

Abstract

In glomerular immune injury, the inducible isoform of nitric oxide synthase (iNOS) becomes a major catalyst of NO production. Although iNOS-catalyzed NO production is sustained and can be cytotoxic, iNOS inhibition exacerbates the magnitude of proteinuria that accompanies immune injury. To investigate putative mechanisms of this effect, we assessed changes in glomerular permeability to albumin by using the following two approaches: (i) an in vivo rat model of glomerular immune injury induced by antibody against the glomerular basement membrane (GBM), in which urine albumin excretion was measured under conditions of iNOS inhibition, and (ii) an ex vivo model of isolated rat glomeruli, in which changes in glomerular capillary permeability to albumin were assessed under conditions of NOS inhibition. In rats with anti-GBM antibody-induced glomerular injury, there was an increase in urine albumin excretion. Treatment with two structurally dissimilar iNOS inhibitors at doses sufficient to decrease urine nitrate and/or nitrite exacerbated proteinuria. In these animals, urine excretion of the isoprostane 8-iso-PGF2alpha (marker of oxidative stress) was increased. In isolated glomeruli incubated with the NOS inhibitor L-NMMA, the permeability to albumin increased. This effect was reversed by the NO donor DETA NONOate and by the superoxide dismutase mimetic Tempol. We conclude that NOS-catalyzed NO production is an important mechanism in regulating glomerular permeability to protein. This mechanism involves control of the bioavailability of superoxide.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16636306     DOI: 10.1177/153537020623100512

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  5 in total

1.  Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.

Authors:  Emily S Robinson; Ursula A Matulonis; Percy Ivy; Suzanne T Berlin; Karin Tyburski; Richard T Penson; Benjamin D Humphreys
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 8.237

2.  Reduction in basal nitric oxide activity causes albuminuria.

Authors:  Christian Ott; Markus P Schneider; Christian Delles; Markus P Schlaich; Roland E Schmieder
Journal:  Diabetes       Date:  2011-02       Impact factor: 9.461

3.  Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial.

Authors:  Thomas Larsen; Frank H Mose; Jesper N Bech; Erling B Pedersen
Journal:  BMC Nephrol       Date:  2013-07-26       Impact factor: 2.388

4.  Free radical scavenging decreases endothelin-1 excretion and glomerular albumin permeability during type 1 diabetes.

Authors:  Mohamed A Saleh; Carmen De Miguel; David I Stevens; Pamela K Carmines; David M Pollock; Jennifer S Pollock
Journal:  Physiol Rep       Date:  2016-12

5.  The lupus-susceptibility gene kallikrein downmodulates antibody-mediated glomerulonephritis.

Authors:  Q-Z Li; J Zhou; R Yang; M Yan; Q Ye; K Liu; S Liu; X Shao; L Li; X-J Zhou; E K Wakeland; C Mohan
Journal:  Genes Immun       Date:  2009-03-05       Impact factor: 2.676

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.